Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).

Abstract: The disclosure provides for eRNA-targeted transcriptional reprogramming through targeted reduction of eRNAs for a clinically relevant gene, TNFSF10, resulting in a selective control of interferon-induced apoptosis. A method of inhibiting a TNFSF10 gene expression in a human cell is disclosed. The methods described herein comprise contacting the human cell with a single-stranded antisense compound consisting of the sequence selected from a set of SEQ ID NOs: disclosed herein, wherein the antisense compound targets an enhancer RNA (eRNA) transcribed from a genomic enhancer sequence or region. The eRNA is an TNFSF10 eRNA sequence comprising the nucleic acid sequence selected from the SEQ ID NOs disclosed herein which inhibits expression of the TNFSF10 gene in the human cell.

Abstract: Methods, apparatuses, systems, and implementations for inductive heating of a foreign metallic implant are disclosed. A foreign metallic implant may be heated via AMF pulses to ensure that the surface of the foreign metallic implant heats in a uniform manner. As the surface temperature of the foreign metallic implant rises, acoustic signatures may be detected by acoustic sensors that may indicate that tissue may be heating to an undesirable level approaching a boiling point. Once these acoustic signatures are detected, the AMF pulses may be shut off for a time period to allow the surface temperature of the implant to cool before applying additional AMF pulses. In this manner, the surface temperature of a foreign metallic implant may be uniformly heated to a temperature adequate to treat bacterial biofilm buildup on the surface of the foreign metallic implant without damaging surrounding tissue.

Abstract: Some methods of analyzing one or more brain lesions of a patient comprise, for each of the lesion(s), calculating one or more lesion characteristics from a first 3-dimensional (3D) representation of the lesion obtained from data taken at a first time and a second 3D representation of the lesion obtained from data taken at a second time that is after the first time. The characteristic(s) can include a change, form the first time to the second time, in the lesion's volume and/or surface area, the lesion's displacement from the first time to the second time, and/or the lesion's theoretical radius ratio at each of the first and second times. Some methods comprise characterizing whether the patient has multiple sclerosis and/or the progression of multiple sclerosis in the patient based at least in part on the calculation of the lesion characteristic(s) of each of the lesion(s).

Abstract: Provided herein are compositions, systems, methods, and kits for peptide analysis, including peptide sequencing. Aspects of the present disclosure provide bifunctional reagents which may selectively couple to amino acids and selectively couple to detectable species. Aspects of the present disclosure further provide methods for using these bifunctional reagents to sequence and analyze peptides.

Abstract: Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).

Abstract: Provided herein are compositions, methods and kits for targeting Cystinosin protein. These compositions, methods and kits may be used for detecting and quantifying Cystinosin in clinical and non-clinical samples.

Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: A biosensing system configured to detect a target DNA and methods of detecting a target DNS are presented. The biosensing system comprises a biosensor comprising a suspension of a hybridization buffer containing dispersed gold nanoparticles, sodium chloride, and single-stranded DNA probes configured to undergo DNA hybridization with the target DNA.

Abstract: Embodiments of the present systems and methods may provide techniques that provide dynamic groups and attribute-based access control (ABAC) model (referred as CV-ABACG) to secure communication, data exchange and resource access in smart vehicles ecosystems. In embodiments, the model not only considers system wide attributes-based security policies, but also takes into account individual user privacy preferences for allowing or denying service notifications, alerts, and operations to on-board resources. Embodiments of the present systems and methods may provide groups in vehicular IoT, which may be dynamically assigned to moving entities like connected cars, based on their current GPS coordinates, speed or other attributes, to ensure relevance of location and time sensitive notification services, to provide administrative benefits to manage large numbers of entities, and to enable attributes inheritance for fine-grained authorization policies.

Abstract: Disclosed herein are methods for modulating an amount or activity of a gene or a gene product in a cell. The methods herein may comprise contacting a cell with a therapeutic agent assembled with a lipid composition, which lipid composition may comprise a dendrimer or dendron which may comprise one or more degradable diacyl group, in which may result in modulating the amount or activity of the gene or the gene product in the cell. The therapeutic agent modulating a gene or gene product in a cell may be sufficient to treat a disease or disorder in a subject. Further disclosed herein are pharmaceutical compositions, kits, and lipid compositions for modulating an amount or activity of a gene or a gene product in a cell.

Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Abstract: Disclosed herein are dendritically porous three-dimensional structures, including hierarchical dendritically porous three-dimensional structures. The structures include metal foams and graphite structures, and are useful in energy storage devices as well as chemical catalysis.

Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH as well as a metal chelating group. In some aspects, the metal chelating group is chelated to a metal ion capable of positron emission. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.

Abstract: Methods of reducing survival of cancer cells in a subject by applying alternating electric fields to the cancer cells and delivering at least one of an E2F inhibitor and a CDK4/6 inhibitor to the cancer cells are provided. In some instances, alternating electric fields are applied to the cancer cells at a frequency between 80 and 300 kHz. In some instances, at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. In some aspects, the alternating electric fields are applied to the cancer cells for at least 72 hours.

Abstract: Compositions and methods for attenuating or preventing lymphoproliferation in a subject are provided. The subject may have, be suspected of having, or at risk of having a lymphoproliferative disease. The methods herein include administering to the subject a composition effective for decreasing phosphofurin acidic cluster sorting protein 1 (Pacs1) expression and/or activity.

Abstract: The present methods use gene therapy to confer inducible nitric oxide synthase (iNOS) expression solely in the tumor space, using focused ultrasound targeting. NOS catalyzes the reaction that generates nitric oxide (NO), a potent endogenous vasodilator. Microbubble-mediated non-viral delivery overcomes major barriers associated with non-viral NO gene therapy. The methods increase tumor perfusion and compound the efficacy of a vast array of chemotherapy, radiotherapy, and immune-based treatments.

Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.

Abstract: The present invention includes a method and apparatus for improved magnetic resonance imaging with simultaneous fat and fluid suppression of a subject comprising: acquiring four images, in-phase (IP) and out-of-phase (OP) at a short and a long echo time (TE) using a single-shot turbo spin echo from one or more magnetic resonance imager excitations: processing at least a pair of IP and OP images at a short and a long TE using single-shot turbo spin echo using a Dixon reconstruction; processing the pair of IP and OP images; subtracting the long TE water-only image from the shared-field-map Dixon reconstruction from the short TE water-only image to provide a fluid attenuation; processing water-only and fat-only images at the short and long TE to generate quantitative fat-fraction map; and reconstructing one or more 3D magnetic resonance images.

Abstract: Certain embodiments are directed to NEIL2 compositions and method of using NEIL2 composition to treat subjects in need of such treatment.